MLRG

101.0950.27%

Eli Lilly’s EloraTZP delivers up to 23.3% average weight loss in Phase 2 trial

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Eli Lilly will present obesity treatment study results at ObesityWeek 2026, running November 14-17 in Washington, D.C. * Phase 2 results showed investigational EloraTZP reduced weight and improved blood sugar control in adults with obesity or overweight and type 2 diabetes. * Phase 3 trials showed investigational retatrutide reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity or overweight. * Zepbound reduced body mass index in adolescents with obesity; more than half no longer met obesity criteria. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611141201PR_NEWS_USPR_____DE96941) on November 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.